



Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.)  
 CVR Payment Statement for Quarter Ending March 31, 2026

<u>Line Item</u>	<u>Calculation Ref</u>	<u>Payments to Date</u> <u>Amount</u>	<u>Q1-2026</u> <u>Amount</u>
Gross Proceeds	<b>A</b>	\$ 23,839,970.00	\$ 30,000,000.00
Permitted Deductions	<b>B</b>	(6,543,247.02)	(22,550.19)
Net Proceeds	<b>C = A + B</b>	17,296,722.98	29,977,449.81
Adjustment Amount	<b>D</b>	(1,000,000.00)	-
<b>CVR Cash Payment</b>	<b>E = C + D</b>	<b>16,296,722.98</b>	<b>29,977,449.81</b>
Holdback, per CVR Payment definition	<b>F = E x 15%</b>	(2,444,508.45)	(4,496,617.47)
<b>CVR Payment</b>	<b>G = E + F</b>	<b>13,852,214.53</b>	<b>25,480,832.34</b>
<b>90% per Section 2.4</b>	<b>H = G x 90%</b>	<b>12,466,993.08</b>	<b>22,932,749.10</b>
<b>Number of Outstanding CVRs</b>		<b>94,280,501</b>	<b>94,280,501</b>
<b>CVR Payment per Outstanding CVR</b>		<b>\$ 0.132233</b>	<b>\$ 0.243240</b>